Diamond Hill Capital Management Inc. Acquires 218,660 Shares of Enovis Co. (NYSE:ENOV)

Diamond Hill Capital Management Inc. boosted its position in shares of Enovis Co. (NYSE:ENOV - Free Report) by 7.8% in the 3rd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 3,004,694 shares of the company's stock after buying an additional 218,660 shares during the quarter. Diamond Hill Capital Management Inc. owned 5.38% of Enovis worth $129,352,000 at the end of the most recent quarter.

Other large investors have also bought and sold shares of the company. River Road Asset Management LLC purchased a new stake in Enovis in the 3rd quarter worth about $51,341,000. American Century Companies Inc. raised its stake in shares of Enovis by 78.6% during the 2nd quarter. American Century Companies Inc. now owns 1,511,871 shares of the company's stock worth $68,337,000 after purchasing an additional 665,208 shares in the last quarter. Magnetar Financial LLC raised its stake in shares of Enovis by 66.7% during the 2nd quarter. Magnetar Financial LLC now owns 1,104,803 shares of the company's stock worth $49,937,000 after purchasing an additional 442,051 shares in the last quarter. Boston Partners raised its stake in shares of Enovis by 206.5% during the 1st quarter. Boston Partners now owns 295,969 shares of the company's stock worth $18,455,000 after purchasing an additional 199,411 shares in the last quarter. Finally, Janus Henderson Group PLC raised its stake in shares of Enovis by 100.6% during the 1st quarter. Janus Henderson Group PLC now owns 378,020 shares of the company's stock worth $23,606,000 after purchasing an additional 189,584 shares in the last quarter. Institutional investors own 98.45% of the company's stock.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently weighed in on the company. Evercore ISI cut their price target on Enovis from $62.00 to $58.00 and set an "outperform" rating for the company in a research note on Tuesday, October 1st. JPMorgan Chase & Co. cut their price objective on Enovis from $53.00 to $50.00 and set a "neutral" rating on the stock in a research note on Thursday, August 8th. JMP Securities initiated coverage on Enovis in a research note on Thursday, October 3rd. They issued an "outperform" rating and a $62.00 price objective on the stock. Finally, Needham & Company LLC reissued a "buy" rating and issued a $65.00 price objective on shares of Enovis in a research note on Thursday. One equities research analyst has rated the stock with a hold rating and eight have issued a buy rating to the company's stock. According to MarketBeat.com, the company has a consensus rating of "Moderate Buy" and an average price target of $67.00.

Enovis Trading Up 2.3 %

NYSE ENOV traded up $1.08 during trading on Monday, hitting $47.50. The company's stock had a trading volume of 168,027 shares, compared to its average volume of 582,344. The company has a debt-to-equity ratio of 0.40, a quick ratio of 1.08 and a current ratio of 2.27. The firm has a 50 day moving average price of $42.23 and a 200 day moving average price of $45.43. Enovis Co. has a 52 week low of $38.27 and a 52 week high of $65.03.

Enovis (NYSE:ENOV - Get Free Report) last issued its quarterly earnings results on Wednesday, November 6th. The company reported $0.73 EPS for the quarter, topping the consensus estimate of $0.62 by $0.11. The company had revenue of $505.22 million for the quarter, compared to the consensus estimate of $504.44 million. Enovis had a positive return on equity of 4.39% and a negative net margin of 5.95%. The company's revenue for the quarter was up 21.0% on a year-over-year basis. During the same period in the previous year, the business posted $0.56 EPS. Equities research analysts predict that Enovis Co. will post 2.79 earnings per share for the current fiscal year.

Enovis Profile

Enovis Corporation operates as a medical technology company focus on developing clinically differentiated solutions worldwide. It also manufactures and distributes medical devices which are used for reconstructive surgery, rehabilitation, pain management, and physical therapy. The company operates through Prevention and Recovery, and Reconstructive segments.